Get the Stockscreener App
1.64
7.87%
-0.14
After Hours:
1.64
Pluri Inc stock is traded at $1.64, with a volume of 28,407.
It is down -7.87% in the last 24 hours and down -19.26% over the past month.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
See More
Previous Close:
$1.78
Open:
$1.79
24h Volume:
28,407
Relative Volume:
1.21
Market Cap:
$17.69M
Revenue:
$1.08M
Net Income/Loss:
$-26.95M
P/E Ratio:
-0.5712
EPS:
-2.8712
Net Cash Flow:
$-21.69M
1W Performance:
-9.89%
1M Performance:
-19.26%
6M Performance:
-50.30%
1Y Performance:
-68.19%
1-Day Range:
$1.60
$1.79
1-Week Range:
$1.60
$1.95
52-Week Range:
$1.5601
$5.68
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
1.64 | 19.21M | 1.08M | -26.95M | -21.69M | -2.8712 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pluri Inc Stock (PLUR) Latest News
Pluri Inc (PLUR) Balance Sheet - TradingKey
PLUR|Pluri Inc|Price:1.780|Chg%:-0.040 - TradingKey
Pluri Inc (PLUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pluri Inc (PLUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enterprise value to revenue forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Enterprise value to revenue forward of Pluri Inc. – FWB:4DX - TradingView
Plurilock Security Inc.'S Aurora Subsidiary Announces Selection as SEWP VI Awardee Enabling U.S. Federal Agencies to Procure It and Cybersecurity Solutions - marketscreener.com
Price to book forward of Pluri Inc. – LS:A408KW - TradingView
Pluri in ongoing talks to extend EIB financing - The Globe and Mail
Pluri Inc. Files 8-K: Company Updates, NASDAQ Listing, and EIB Loan Discussions – July 2026 - Minichart
Pluri chairman raises stake above 30%; shares up - MSN
Pluri's Chairman Increases Investment and Ownership Stake (PLUR) - GuruFocus
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30% - marketscreener.com
Pluri Chairman Builds 30%-Plus Position With $17M Investment - Stock Titan
Pluri Receives Nasdaq Non-Compliance Notice, Faces Delisting Risk - TipRanks
Pluri Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Pluri (PLUR) director Doron Shorrer files Form 3 listing share holdings - Stock Titan
PLURPluri Inc Latest SEC Filings - Finviz
Pluri Inc. Q2 2026 Earnings: EPS Misses Estimates as Stock Holds SteadyDividend Increase Stocks - dars.gov.et
Pluri Inc. Q2 2026 Earnings: Wider-than-Expected Loss Drives Stock DeclineSlow Growth Warning - dars.gov.et
Pluri (NASDAQ: PLUR) director logs RSU grant as 625,000 warrants expire - Stock Titan
Synthetic Stem Cell Market to Witness Massive Growth by 2033 | - openPR.com
Form 13D/A Pluri Inc. For: 1 July By Investing.com - Investing.com UK
Price to sales forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Enterprise value to EBITDA forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Price to earnings forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Price to earnings forward of Pluri Inc. – TASE:PLUR - TradingView
Pluri Inc. Actuals & Estimates (NASDAQ:PLUR) - TradingView
Pluri Inc. Actuals & Estimates (FWB:4DX) - TradingView
Pluri Inc. Actuals & Estimates (TASE:PLUR) - TradingView
Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Brevel and Coffeesai Trial Illuminated Fermentation to Push Cell-Based Coffee Toward Commercial Scale - Cultivated X
RGNT PE Ratio & Valuation, Is RGNT Overvalued - Intellectia AI
Pluri Secures Insider Advance Subscription to Boost Liquidity - TipRanks
Pluri (NASDAQ: PLUR) gets $1,250,000 insider advance and appoints new director - Stock Titan
PLUR Q1 2026 Earnings: EPS Miss Drives Double-Digit Stock DeclineManagement Tone Analysis - dars.gov.et
Pluri Inc (PLUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pluri Inc (PLUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pluri Inc (PLUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pluri Inc (PLUR) Institutional Confidence - TradingKey
Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BSX Q1 2026 Earnings: Slight EPS Beat as Core Segments Show ResilienceEPS Growth Report - newsline.com
Pluri Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Operational InvestmentsEPS Growth Report - dars.gov.et
Pluri Inc. (PLUR) Edges Higher as Stock Nears Key Resistance LevelMarket Leader Picks - newsline.com
Elon Musk Reaches Trillion-Dollar Milestone as SpaceX Nasdaq Debut Propels Net WorthBook Value Growth - newsline.com
Pluri Inc. Q1 2026 Earnings: EPS Misses as Pre-Revenue Biotech Continues Pipeline DevelopmentReturn On Assets - newsline.com
SBSI Q1 2026 Earnings: EPS Surpasses Estimates, No Revenue Data ProvidedAnnual Earnings Summary - newsline.com
PLUR Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueDividend Increase Stocks - DonanımHaber
PLUR Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentHealthcare Earnings Report - newsline.com
UnitedHealth Raises Dividend 5% Amid Rising Healthcare CostsEarnings Decline Risk - newsline.com
Made Scientific, Pluristyx launch development and manufacturing partnership - ROI-NJ
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):